Responses
Immune cell therapies and immune cell engineering
Original research
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.